Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Sep 16, 2013; 1(6): 187-190
Published online Sep 16, 2013. doi: 10.12998/wjcc.v1.i6.187
Published online Sep 16, 2013. doi: 10.12998/wjcc.v1.i6.187
Recurrent epithelial ovarian cancer and hormone therapy
Yoshihito Yokoyama, Hideki Mizunuma, Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8652, Japan
Author contributions: Yokoyama Y and Mizunuma H contributed to this paper.
Supported by The Karoji Memorial Fund of the Hirosaki University Graduate School of Medicine
Correspondence to: Yoshihito Yokoyama, MD, Associate Professor of Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki 036-8652, Japan. yokoyama@cc.hirosaki-u.ac.jp
Telephone: +81-172-395107 Fax: +81-172-376842
Received: April 24, 2013
Revised: May 21, 2013
Accepted: August 4, 2013
Published online: September 16, 2013
Revised: May 21, 2013
Accepted: August 4, 2013
Published online: September 16, 2013
Abstract
The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase II clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.
Keywords: Recurrent ovarian cancer, Hormone therapy, Letrozole, Anastrozole, Tamoxifen, Fulvestrant
Core tip: If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.